Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA User Fee Negotiations: A Big-Firm Coalition Tackles The Big Backlog

Executive Summary

FDA has long negotiated its brand user fee program with two distinct but closely aligned industry groups: the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. Now the agency will be using those same discussion techniques as it develops the generic drug user fee program.

You may also be interested in...



"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

Hospira The Holdout

The Generic Pharmaceutical Association's reunification is not entirely complete. Hospira, alone among large firms that had left the association, has opted to remain a former member.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel